---
document_datetime: 2023-09-21 19:10:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/remicade-epar-procedural-steps-taken-authorisation_en.pdf
document_name: remicade-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3780247
conversion_datetime: 2025-12-24 23:32:32.554458
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Centocor B.V. submitted on 5 March 1998 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Remicade, in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Dr. P. Sj√∂berg

Co-Rapporteur:

Dr. M. Haase

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 27 March 1998.
- The Rapporteur's first assessment report was circulated to all CPMP Members on 8 June 1998. The  Co-Rapporteur's first assessment report was  circulated  to  all  CPMP  Members  on 3 June 1998.
- During the meeting on 21 July 1998 the CPMP agreed on the consolidated list of questions to be sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the  company  on 22 July 1998.
- The company submitted the responses to the consolidated list of questions on 30 November 1998.
- The  Rapporteur/Co-Rapporteur  circulated  the  response  assessment  report  on  the  company's responses to the list of questions to all CPMP Members on 25 January 1999.
- The CPMP during their meeting on 24 February 1999 discussed the joint assessment report and decided to stop the clock for an oral presentation on clinical issues in March. A list of outstanding clinical and quality issues was adopted by the CPMP.
- Oral  explanations  were  given  by  the  Applicant  on  23  March  1999.  The  CPMP  decided  to convene  an  expert  group  to  address  specific  clinical  points  (ANNEX  4.6).  Supplementary information with reference to ongoing studies on safety and post-marketing data on efficacy was requested from the applicant.
- The BWP during their meeting on 11 May 1999 prepared a recommendation to the CPMP on the outstanding quality aspects.
- An ad-hoc experts group meeting took place on 17 May 1999 to address open clinical issues on Remicade. The group prepared a recommendation to the CPMP on these issues.
- During the meeting on 18-20 May 1999 the CPMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Remicade on 19 May 1999.
- The CPMP opinions were forwarded, in all official  languages  of  the  European  Union,  to the European Commission, which adopted the corresponding Decisions on 13 August 1999.